Regeneron Pharmaceuticals (REGN)
EBITDA
$5.75B
TTM · Period ending: · USD
REGN EBITDA
Latest reported$5.75Bperiod ending
Latest reported$5.75Bperiod ending
REGN TTM EBITDA (-$3.30M → $5.75B)
TTM EBITDA
High-resolution chart · PNG
REGN ebitda history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | EBITDA (USD) |
|---|---|
| -52,595,000 | |
| -38,766,000 | |
| -32,938,000 | |
| -24,524,000 | |
| -14,391,000 | |
| -19,054,000 | |
| -21,200,000 | |
| -26,900,000 | |
| -24,400,000 | |
| -15,400,000 | |
| -9,700,000 | |
| -1,900,000 | |
| -300,000 | |
| -4,300,000 | |
| -3,200,000 | |
| -8,400,000 | |
| -11,200,000 | |
| -10,900,000 | |
| -11,200,000 | |
| -9,700,000 | |
| -7,600,000 | |
| -5,200,000 | |
| -2,500,000 | |
| -5,000,000 | |
| -6,800,000 | |
| -16,000,000 | |
| -25,000,000 | |
| -31,400,000 | |
| -37,300,000 | |
| -37,400,000 | |
| -36,400,000 | |
| -31,600,000 | |
| -28,200,000 | |
| -22,100,000 | |
| -16,400,000 | |
| -14,300,000 | |
| -11,500,000 | |
| -10,300,000 | |
| -5,500,000 | |
| -9,100,000 | |
| -5,500,000 | |
| -2,500,000 | |
| -3,300,000 |